Primatene Mist First-Quarter Sales Grow 43% As Amphastar Expands Distribution
Sales of Primatene Mist and other higher-margin products drive Amphastar's ifrst-quarter r5esults. The company continues to target a combined market worth around $10.5bn with seven generics in development.
You may also be interested in...
In addition to distributing to Target stores, TV, radio and digital advertising and late-2020 start of sales at Kroger stores are driving Primatene Mist sales growth. The epinephrine aerosol inhaler's sales increased 186% in 2020 to $51.7m and 47% in Q4 to $13.4m.
Amphastar announces that it has seven generic and three biosimilar products in development in order to target bigger markets. The company revealed that its insulin program is also developing towards interchangeable status.
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.